Onco Wiki / Biomarker

Anti-Müllerian Hormone (Ovarialreserve — BSO-Zeitpunkt bei BRCA-Beförderern)

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDBIO-AMH-OVARIAN-RESERVE
ArtBiomarker
Aliase
AMHAnti-Müllerische HormoneMISMüllerian hemmende SubstanzАнтимюллерів гормон (оваріальний резерв — час BSO у носіїв BRCA)
Statusreviewed 2026-05-18 | pending_clinical_signoff
ErkrankungenDIS-OVARIAN
QuellenSRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025

Biomarker-Fakten

Biomarker-Typserum_marker
Messung
VerfahrenSerumimmunassay (ECLIA, CLIA); zyklisch-tagesunabhängig
Einheitenng/ml (oder pmol/L; Umrechnung 1 ng /ml - 7,14 pmol /L)
Typischer Bereich
  • 0.5
  • 5.0
Verwandte BiomarkerNone declared

Anmerkungen

Granulosa-cell-derived hormone reflecting primordial follicle pool; best single biomarker of ovarian reserve. Adjunct to risk-reducing bilateral salpingo-oophorectomy (RRSO) counseling in BRCA1/BRCA2 germline carriers and other HBOC syndromes (BRIP1, RAD51C, RAD51D, PALB2). NCCN 2025 (Genetic/Familial High-Risk: Breast/Ovarian): BRCA1 RRSO recommended at age 35-40 (after completion of childbearing); BRCA2 at age 40-45. AMH supports timing discussion — declining AMH (<1.0 ng/mL = diminished reserve) helps quantify remaining reproductive window and informs fertility-preservation referral (oocyte/embryo cryopreservation) before RRSO. NOT a screening test for ovarian cancer (CA-125 + TVUS combination has been evaluated and is NOT recommended for screening per UKCTOCS — no mortality benefit). Used in pediatric ovarian function monitoring after gonadotoxic chemotherapy (childhood cancer survivors). Falsely elevated in granulosa-cell tumors and PCOS; falsely suppressed by hormonal contraceptives. STUB pending two-Co-Lead signoff.

Verwendet von

Therapeutische Relevanz